BridgeBio Pharma stock is trading -14.73% below its average target price of $47.17 after marking a 4.6% during today's evening session. Analysts are giving the small-cap Pharmaceutical company an average rating of buy and target prices ranging from $28.0 to $60.0 per share.
The stock has an unusually large proportion of its shares sold short at 15.0%, and a short ratio of 12.74. Since 5.76% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 94.8% of BridgeBio Pharma's shares being owned by this investor type.
Institutions Invested in BridgeBio Pharma
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | Kohlberg Kravis Roberts & Co. L.P. | 18% | 31,060,971 | $1,249,272,291 |
| 2023-09-30 | Viking Global Investors, L.P. | 14% | 25,120,991 | $1,010,366,288 |
| 2023-09-30 | Vanguard Group Inc | 6% | 11,275,981 | $453,519,969 |
| 2023-09-30 | Blackrock Inc. | 5% | 9,249,943 | $372,032,718 |
| 2023-09-30 | Aisling Capital Management LP | 3% | 6,068,125 | $244,059,994 |
| 2023-09-30 | Laurion Capital Management, LP | 3% | 5,651,039 | $227,284,795 |
| 2023-09-30 | State Street Corporation | 3% | 5,040,414 | $202,725,457 |
| 2023-09-30 | Cormorant Asset Management, LP | 3% | 4,662,530 | $187,526,962 |
| 2023-09-30 | HHLR Advisors, LTD | 2% | 2,782,750 | $111,922,208 |
| 2023-09-30 | Pictet Asset Management Holding SA | 2% | 2,740,022 | $110,203,688 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on BridgeBio Pharma.
